Rivus Pharmaceuticals Announces New Data from Phase 2 M-ACCEL Trial of HU6 in MASH in Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025

Trial met primary endpoint, with statistically significant reductions in liver fat observed in all HU6 treatment groups –– In addition to ...
National Security Journal on MSN

Mach 2 F-47 NGAD 6th Generation Fighter Keeps Chinese Generals Up At Night

The F-47 NGAD is pitched as a true leap: a long-range, Mach-2-plus stealth “quarterback” that commands swarms of ...
The Lancet

Caution on the use of α2δ-ligands in neuropathic pain – Authors' reply

We appreciate the constructive remarks by Chung-Wei Christine Lin and colleagues regarding our systematic review and resulting recommendations.1 Our systematic review and meta-analysis were explicitly ...